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Background: Differentiated thyroid cancer (DTC) has excellent long term survival in most patients. Long-term
treatment related morbidity is therefore important, but may not be well characterised. The aim of this study was
to conduct an electronic survey of clinicians involved in the care of patients with DTC to determine their views
on treatment related morbidity.
Methods: A nine item questionnaire was developed, piloted locally and sent by email to members of three United
Kingdom (UK) medical organisations (Thyroid Cancer Forum, British Association of Endocrine and Thyroid Surgeons,
British Thyroid Association).
Results: 125 responses were received. Less than 5% of respondents had a formal protocol to detect morbidity
associated with TSH suppression. Over 50% agreed that morbidity from TSH suppression is not well defined. The
majority of responders also agreed that the long-term morbidity of hypocalcaemia, significant voice change and
TSH suppression in DTC are not well characterised. Physicians perceived treatment related morbidity to be a bigger
problem than surgeons (P = 0.019).
Conclusion: Clinicians treating thyroid cancer agree that long-term treatment related morbidity from DTC is not
well characterised. A study of the prevalence and severity of treatment related morbidity and its impact on health
of patients with DTC is warranted.
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The standard treatment regimen in most patients with
differentiated thyroid cancer (DTC) includes thyroidec-
tomy, radio-iodine (RAI) ablation and thyroid stimulat-
ing hormone (TSH) suppression therapy [1]. Diagnosis
of DTC is associated with an excellent 10 and 20 year
survival [2]. Long term treatment related morbidity is
therefore important and includes post-thyroidectomy
hypocalcaemia, the effects of TSH suppression therapy
and significant voice change.
A retrospective study of 316 patients who underwent
thyroidectomy for DTC found rates of transient and per-
manent hypocalcaemia to be 27.5% and 5.1% respectively
[3]. Hypocalcaemia commonly presents with paraesthesia,
muscle twitching and spasms. In more severe cases, pa-
tients may develop tetany, seizure and cardiac arrhythmias* Correspondence: ovieedafe@hotmail.co.uk
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unless otherwise stated.[4]. Long term hypoparathyroidism is associated with renal
impairment, basal ganglia calcifications and damage to
bone health [5,6].
Recurrent laryngeal nerve palsy is another potential
complication following thyroid surgery and can signifi-
cantly affect voice, swallowing and predispose to aspir-
ation. Temporary and permanent recurrent laryngeal
nerve palsy can occur in up to 8% and 3% of patients
respectively [7]. Bilateral nerve palsy is rare and may oc-
casionally necessitate a tracheostomy. In addition to re-
current laryngeal nerve injury, other factors affecting the
quality of voice postoperatively include injury/damage to
the superior laryngeal nerves, strap muscle injury and ir-
ritation or oedema of the airways [8]. Postoperative voice
change after thyroidectomy can have a significant impact
on an individual’s personal and professional life [9].
Although traditional practice was to continue lifelong
TSH suppression treatment for all patients with thyroid
cancer, recent guidelines from the American Thyroidtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Do you see patients with the following problems following treatment for DTC?
Complication (number
of responders)
Never/NA Rarely (≤1/year) Occasionally (≤1/month) Commonly (≤6/month) Frequently (>6/month)
Temporary hypocalcaemia (118) 9 (7.6%) 18 (15.3%) 63 (53.4%) 28 (23.7%) 0 (0.0%)
Long term hypocalcaemia (118) 10 (8.5%) 51 (43.2%) 43 (36.4%) 14 (11.9%) 0 (0.0%)
Significant voice change (117) 6 (5.1%) 70 (59.8%) 36 (30.8%) 5 (4.3%) 0 (0.0%)
Symptoms/poor quality of life
from TSH suppression (118)
19 (16.1%) 57 (48.3%) 30 (25.4%) 12 (10.2%) 0 (0.0%)
Bone/CVS complications
from TSH suppression (118)
41 (34.7%) 58 (49.2%) 19 (16.1%) 0 (0.0%) 0 (0.0%)
NA, not applicable; CVS, cardiovascular; TSH, thyroid stimulating hormone.
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to less than 0.1 mU/l for initial management for DTC in
high risk patients and a lower degree of TSH suppres-
sion (to between 0.1-0.5 mU/l) for low risk patients [10].
The guideline also recommended the TSH level be sup-
pressed long term in patients with persistent disease. It
is also suggested that TSH be kept at the lower limit of
normal for 5-10 years in patients who were high risk at
presentation and subsequently show no residual disease.
Recent European guidelines suggest that patients who
are free of thyroid cancer following treatment may be
shifted from suppression to replacement, regardless of
their initial risk [1]. There are no recommendations
regarding TSH suppression in DTC patients with pre-
existing bone and cardiovascular disease. Here, clinicians
must balance risk from thyroid cancer recurrence and
risk of bone and cardiac morbidity from TSH suppres-
sion [11].
A prospective study found that TSH suppression
following thyroidectomy for PTC in women aged 50 or
over was associated with a significant reduction in bone
mineral density (BMD) one year after surgery [12]. In a
multicentre prospective study, Bauer et al. evaluated the
associated between low TSH and fracture risk in women
aged 65 or over. They found that a suppressed TSH level
(0.1 mU/L) increased the risk of hip and vertebrae
fracture by threefold and fourfold respectively in multi-
variable analysis [13]. A systematic review evaluating
the effects on bone metabolism of long term TSH sup-
pression found postmenopausal women to be at increasedTable 2 Do you have a locally agreed protocol for the detecti
DTC?
Complication (number of responders) NA/Not involved Don’t know
Temporary hypocalcaemia (118) 1 (0.8%) 1 (0.8)
Long term hypocalcaemia (117) 2 (1.7%) 0 (0.0%)
Significant voice change (118) 2 (1.7%) 2 (1.7%)
Symptoms/poor quality of life
from TSH suppression (118)
14 (11.9%) 5 (4.2%)
Bone/CVS complications
from TSH suppression (118)
17 (14.4%) 8 (6.8%)
NA, not applicable; CVS, cardiovascular; TSH, thyroid stimulating hormone.risk of low BMD [14]. The authors recommended mea-
surements of BMD in postmenopausal women with DTC
starting TSH suppression therapy. A prospective study
examined BMD in 26 pre-menopausal women having long
term TSH suppression therapy for DTC [15]. They found
significant reduction in BMD of femoral neck, femoral
trochanter and Ward’s triangle at one-year and four-years
following treatment.
The long term effect of TSH suppression on BMD, in-
cluding low impact fracture rate in males has also been
studied [16]. Authors found no difference in BMD or frac-
ture rates between men on long term TSH suppressive ther-
apy (mean ± SD duration of treatment; 15 ± 5 years) and
controls. However, the study group was limited by a small
sample size of 33; large sample size is required to adequately
study the effect on TSH suppression on fracture rates as
frequency of fractures are low in the population [16].
Adverse cardiovascular effects and symptoms associated
with long term TSH suppression for DTC have been re-
ported by various studies [17-19]. Patients receiving TSH
suppression scored higher for symptoms mimicking
increased adrenergic activity including palpitations and in-
creased heart rate compared to controls [17]. One study
found a significant reduction in exercise tolerance in pa-
tients with long term TSH suppression for DTC compared
to matched controls [18]. This study also found significant
changes in cardiac morphology including greater intra-
ventricular thickness and left ventricular posterior wall
thickness in patients with long term TSH suppression for
DTC compared to controls. An increase in ventricularon of the following problems following treatment for
No agreed arrangements Informal arrangements Formal protocol
7(5.9%) 32 (21.7%) 77 (65.3%)
13 (11.1%) 51 (43.6%) 51 (43.6%)
20 (16.9%) 61 (51.7%) 33 (28.0%)
43 (36.4%) 53 (44.9%) 3 (2.5%)
47 (39.8%) 42 (35.6%) 4(3.4%)
Table 3 Treatment related morbidity is a significant clinical problem in patients with DTC
Profession NA Strongly disagree Disagree Neutral Agree Strongly agree
Surgeons 0 (0.0%) 4 (5.0%) 40 (50.0%) 15 (18.8%) 17 (21.2%) 4 (5.0%)
Physicians 0 (0.0%) 0 (0.0%) 12 (31.6% 10 (26.3%) 14 (36.8%) 2 (5.3%)
NA, not applicable.
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also confirmed by another group [19].
Aims and objectives
This project aims to understand perceptions of clinicians
involved in the management of DTC on long term treat-
ment related morbidity. The objectives were to conduct
an internet based survey of clinicians involved in the
care of patients with DTC to understand their percep-
tions of treatment related morbidity, with particular
reference to hypocalcaemia, significant voice change and
TSH suppression.
Methods
A questionnaire survey incorporating nine items was de-
signed to address information pertinent to the objectives
outlined above. A web based tool (http://www.survey-
monkey.com) was used to create the questionnaire. Re-
sponses to treatment related morbidities were recorded
on a Likert scale.
A pilot version was sent via email (embedded link to the
web survey) to consultants involved in the care of patients
with DTC. This was done to get feedback on the structure,
appropriateness for purpose, design and usability of the
web survey. The survey was amended in accordance with
feedback received from three consultants.
All nine questions were included on one web page.
Responders were able to change their answers during
the survey; however, once submitted they were unable to
review or change their answers. The survey was sent via
email to doctors involved in the treatment of patients
with thyroid cancer. These doctors were approached via
national organisations in the UK whose members were
doctors likely to be involved in thyroid cancer manage-
ment. An email explaining the study and a link to the
online survey was then forwarded by the secretaries of
the organisations to their members.Table 4 The incidence/prevalence of the following problems a
for DTC
Complication (number of responders) Strongly agre
Temporary hypocalcaemia (118) 16 (13.6%)
Long term hypocalcaemia (118) 16 (13.6%)
Significant voice change (117) 14 (12.0%)
Symptoms/poor quality of life from TSH suppression (118) 6 (5.1%)
Bone/CVS complications from TSH suppression (118) 5 (4.2%)
NA, not applicable; CVS, cardiovascular; TSH, thyroid stimulating hormone.The following UK organisations were contacted: British
Association of Thyroid and Endocrine Surgeons (BAETS),
Thyroid Cancer Forum (TCF) and the British Thyroid
Association (BTA) with approximately 200, 230 and 150
members respectively. Considerable membership overlap
exists between the organisations. A reminder email was
sent 7-12 weeks after initial contact to all organisations.
The survey remained open for at least four weeks after the
second reminder.
A combination of IP address, response date and time
was used to detect multiple entries being recorded on
the electronic survey. In cases where the questionnaires
were terminated early, completed questions were included
in data analysis. Any unanswered questions/missing values
were excluded from data analysis. All responses were
downloaded and exported directly into Microsoft Excel
2007 with a Survey Monkey professional account. This
avoided errors associated with manual data entry.Data analysis
Percentages were used to summarise responses. The out-
come measure was on a Likert scale (of 4 to 6 points). The
Mann-Whitney U test was used to calculate differences in
perception of treatment related morbidity between sur-
geons and physicians (oncologist, endocrinologist and nu-
clear medicine physician) and between clinicians seeing
higher (>12 patients per month with DTC) and lower (≤12
patients per month with DTC) volumes of patients. The
significance level was set at 0.05.Ethical consideration
Ethics approval was obtained from the University of
Sheffield Medical School Ethics Committee and the
study was conducted in accordance to the submitted
protocol [SMBRER244]. An amendment was obtained to
send an email reminder to all potential participants.re not well defined in patients undergoing treatment
e Disagree Neutral/don’t know Agree Strongly agree
47 (39.8%) 8 (6.8%) 42 (35.6%) 5 (4.2%)
50 (42.4%) 9 (7.6%) 37 (31.4%) 6 (5.1%)
42 (35.9%) 12 (10.3%) 42 (35.9%) 7 (6.0%)
10 (8.5%) 24 (20.3%) 62 (52.5%) 16 (13.6%)
10 (8.5%) 27 (22.9%) 59 (50.0%) 17 (14.4%)
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A total of 77 responses were received following initial
contact by email. The total number of responses in-
creased to 125 following the second reminder. Four re-
sponders were excluded from analysis as they were from
outside the UK. A further three were also excluded from
analysis as they were not involved in the management of
patients with DTC. A total of 118 responses were
analysed.
A response rate was not calculated as significant over-
lap exists between memberships of the organisation and
collection of details that may identify members was not
allowed. All responders were assumed to be consultants
or senior trainees.
Background of the respondents
The responders included 80 surgeons (67.8%), 19 oncol-
ogists (16.1%), 16 endocrinologists (13.6%) and 3 nuclear
medicine physicians (2.5%). The approximate number of
patients (new and follow up) with DTC (at any stage
of treatment) seen each month by responders was as
follow: less than one, 11 (9.3%); between one and six,
52 (44.1%); between six and twelve, (17.8%) and more
than twelve, 34 (28.8%). Eighty four of 118 (72.2%) and
34/118 (28.8%) of the responders were considered to be
seeing lower and higher volumes of patients respectively.
Table 1 shows the number/frequency of patients seen
with treatment related morbidity by responders. Table 2
shows responses to the question: ‘Do you have a locally
agreed protocol for the detection of the following prob-
lems following treatment for DTC? The proportion of
clinicians who had a formal protocol for detecting tem-
porary hypocalcaemia, long term hypocalcaemia, signifi-
cant voice change, symptoms/poor quality of life from
TSH suppression, and bone and cardiovascular compli-
cation of TSH suppression were 65.3%, 43.6%, 28.0%,
2.5% and 3.4% respectively (Table 2).
Table 3 shows clinicians’ perceptions of the clinical
significance of treatment related morbidity in DTC.
Physicians perceived treatment related morbidity to be
a bigger problem than surgeons (P = 0.019). Table 4
shows clinicians’ perceptions on how well the incidence
of treatment related morbidity is defined. Clinicians
seeing higher volumes of patients with DTC were more
likely to agree that the incidence of the following com-
plications is not well defined: temporary hypocalcaemiaTable 5 The long term morbidity of the following are not we
Complication (number of responders) Strongly agree Disag
Hypocalcaemia (118) 7 (5.9%) 32 (27
Significant voice change (117) 12 (10.3%) 34 (29
TSH suppression (116) 6 (5.2%) 19 (16
NA, not applicable; CVS, cardiovascular; TSH, thyroid stimulating hormone.(P = 0.014), long term hypocalcaemia (P = 0.042) and sig-
nificant voice change (P = 0.028). Table 5 shows clini-
cians’ perceptions of the characterisation of long term
treatment related morbidity in DTC. Most clinicians
agreed that the characterisation of long term treatment
related morbidity of the following are not well defined:
hypocalcaemia (55.1%), significant voice change (50.5%)
and TSH suppression (57.7%).Discussion
To our knowledge this is the first survey evaluating
perceptions of clinicians on treatment related morbidity
of DTC.
Although almost half of the clinicians perceived mor-
bidity associated with TSH suppression to be ‘rarely’
identified in clinic; only 2.5% and 4.0% had a formal
protocol for detecting symptoms/poor quality of life
from TSH suppression, and bone and cardiovascular
complications respectively. It is unclear whether a lack
of a formal protocol to detect these complications plays
a role in the perception of morbidity. In addition, clini-
cians seeing higher volumes of patients with DTC per-
ceived a higher frequency of long term hypocalcaemia,
significant voice change and morbidity associated with
TSH suppression (P < 0.05).
The lack of formal protocol to detect treatment related
morbidity has also been confirmed by a recent survey of
Japanese hospitals. They found most hospital did not
perform BMD measurements in patients with TSH sup-
pression for DTC. Less than 30% of hospitals routinely
measure BMD in patients receiving TSH suppression for
DTC. Of the hospitals that routinely measure BMD,
measurements were taken yearly or twice yearly (44%),
while 56% had no agreed interval for measurement [20].
Over 50% of clinicians perceived that the incidence of
symptoms/poor quality of life from TSH suppression,
and bone and cardiovascular complications of TSH sup-
pression are not well defined. The picture was less clear
with regards to temporary hypocalcaemia, long term
hypocalcaemia and significant voice change: approxi-
mately equal numbers of clinicians ‘agree’ and ‘disagree’
with the statement. Further analysis revealed that higher
volume clinicians perceived that the incidence of tem-
porary hypocalcaemia, long term hypocalcaemia and
significant voice change are not well defined (P < 0.05).ll characterised
ree Neutral/don’t know Agree Strongly agree
.1%) 14 (11.9%) 59 (50.0%) 6 (5.1%)
.1%) 12 (10.3%) 54 (46.2%) 5 (4.3%)
.4%) 24 (20.7%) 57 (49.1%) 10 (8.6%)
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term morbidity of hypocalcaemia, significant voice change
and TSH suppression are not well characterised. This in
context of the overall perceptions over the clinical signifi-
cance of treatment related morbidity (44.1% of clinicians
perceived treatment related morbidity not to be a signifi-
cant clinical problem) is of particular interest. One could
postulate that it is difficult to ascertain the scale of a prob-
lem that is not well characterised or ill-defined.
One limitation of this survey was the inability to calcu-
late the response rate due to significant overlaps be-
tween institutions contacted. The significance of bias
due to non-response is therefore unclear. The potential
impact of non-responders cannot be ignored as they
may not have perceived treatment related morbidity in
DTC to be a significant clinical problem. The survey
only targeted surgeons and physicians who are members
of specific organisations (TCF, BAETS and BTA), the
findings may not be applicable to the entire population
of thyroid surgeons and physicians.
The results reported are clinicians’ perceptions of
treatment related morbidity; it may not mirror the
reality or true scale of the problem. The results could
have been skewed as surgeons represented the majority
(67.8%) of the sample given; particularly, given that
physicians seemed to perceive greater treatment related
morbidity than surgeons. The difference between physi-
cians and surgeons could be attributed to differences in
current follow up protocols. The extent to which these
groups of clinicians are involved in the follow up man-
agement of thyroid cancer patients is unclear and was
not investigated in this survey. Another limitation of the
survey was the relatively small proportion of clinicians
seeing higher volumes of patients with DTC (28.8%); al-
though it could be argued that this is more representa-
tive of current practice. This survey did not evaluate
perceptions of morbidity associated with radioiodine ab-
lation. Ascertainment of morbidity attributed to radioio-
dine ablation is important.
Conclusion
There is a lack of formal protocols to detect complications
associated with TSH suppression and most clinicians
agreed that the incidence of complications associated with
TSH suppression is not well defined. Over 50% of clini-
cians agreed that the long term morbidity of hypocalcae-
mia, significant voice change and TSH suppression are
not well characterised. Physicians perceived treatment re-
lated morbidity to be a bigger problem than surgeons; this
difference in perception could be related to differences in
current follow up practices and differences in medical and
surgical literature. A study of the prevalence and severity
of treatment related morbidity and its impact on health of
patients with DTC is warranted.Abbreviations
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